Περίληψη:
Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10-5; 17% at 10-6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts' and tumor-associated monocytes/macrophages' predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10-6. © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.
Συγγραφείς:
Terpos, E.
Kostopoulos, I.V.
Kastritis, E.
Ntanasis-Stathopoulos, I.
Migkou, M.
Rousakis, P.
Argyriou, A.T.
Kanellias, N.
Fotiou, D.
Eleutherakis-Papaiakovou, E.
Gavriatopoulou, M.
Ziogas, D.C.
Papanota, A.-M.
Spyropoulou-Vlachou, M.
Trougakos, I.P.
Tsitsilonis, O.E.
Paiva, B.
Dimopoulos, M.A.
Λέξεις-κλειδιά:
bortezomib; daratumumab; immunoglobulin A; immunoglobulin D; immunoglobulin G; melphalan, adult; aged; Article; B lymphocyte subpopulation; bone marrow biopsy; controlled study; disease association; drug megadose; erythroblast; female; flow cytometry; follow up; high throughput sequencing; human; maintenance therapy; major clinical study; male; middle aged; minimal residual disease; multiple myeloma; phenotype; priority journal; prospective study; treatment duration; tumor diagnosis; tumor volume
